The engagement of high-affinity receptors for IgE (FcεRI) generates both positive and negative signals whose integration determines the intensity of mast cell responses. FcεRI positive signals are also negatively regulated by low-affinity receptors for IgG (FcγRIIB).
Immunoreceptor Tyrosine-based Activation Motif (ITAM). Upon receptor aggregation, ITAMs are phosphorylated by the raft-associated src family tyrosine kinase Lyn (9, 10) .
Phosphorylated ITAMs subsequently recruit SH2 domain-containing protein tyrosine kinases and adapters that initiate the constitution of signaling complexes where intracellular enzymes an substrates can meet and interact. One critical metabolite is phosphatidylinositol (3,4,5)-trisphosphate (PIP3) which mediates the recruitment of molecules that contain a plekstrin homology (PH) domain (11) . Two consequences of these interactions are an increase in the concentration of intracellular Ca 2+ and the activation of MAPKs that activate transcription factors. Altogether, these events lead to exocytosis and the subsequent release of granular mediators, to the production of newly formed lipid-derived inflammatory mediators, to the transcription of cytokine genes and the secretion of their products. FcγRIIB are single-chain receptors that bind IgG immune complexes with a high avidity. They contain one
Immunoreceptor Tyrosine-based Inhibition Motif (ITIM) in their intracytoplasmic domain.
Upon coaggregation with FcεRI by immune complexes, FcγRIIB inhibit mast cell activation (12) . Coaggregation enables the FcεRI-associate kinase lyn to phosphorylate the ITIM of FcγRIIB (13) . When phosphorylated, FcγRIIB recruit the SH2 domain-containing 5'-inositol phosphatase SHIP1 (14) . SHIP1 was shown to be necessary and sufficient for FcγRIIB-dependent negative regulation (15) . It interferes with positive signaling by two mechanisms.
By dephosphorylating PIP3, it prevents the recruitment of molecules with a PH domain and the subsequent Ca 2+ mobilization (16) . By recruiting rasGAP via the adaptor molecule Dok-1, it down regulates the activation of MAPKs and the subsequent cytokine gene transcription (17) .
Lipid rafts have been shown to play an essential role in organizing positive signaling by FcεRI. Disruption of rafts, using cholesterol-depleting drugs, dramatically decreases early phosphorylation events induced upon FcεRI aggregation (18). According to a current model, FcεRI are excluded from rafts in resting mast cells, whereas signaling proteins covalently associated with saturated fatty acids, like Lyn (19) and LAT (20) , are concentrated in these domains. Upon aggregation, FcεRI translocate into rafts (21) which coalesce (22), bringing in proximity FcεRI and raft-associated signaling proteins. Unlike rafts, the sub-membranous Factin skeleton does not seem to be critical for FcεRI-dependent positive signaling.
Observations suggest on the contrary, that the sub-membranous F-actin skeleton is involved in constitutive negative regulation of FcεRI signaling. Indeed, drugs such as latrunculin, which prevent actin polymerization, increase the rate and extent of antigen-induced degranulation (23). The inhibition of mast cell activation observed in excess of antigen is correlated with an association of FcεRI with actin microfilaments (24). SHIP1 was previously
shown to constitutively down-regulate FcεRI signaling. Bone Marrow-derived Mast Cells (BMMCs) from SHIP1 -/-mice indeed develop increased IgE-induced responses compared to
BMMCs from wild-type littermates (25). Interestingly, SHIP1 and the related phosphatase SHIP2 were reported to associate with the sub-membranous F-actin skeleton upon thrombin activation in human platelets (26, 27) . In COS7 cells, the actin-binding protein filamin-1, was
shown to mediate the constitutive association of SHIP2 with the sub-membranous F-actin skeleton (28) .
Taken together, the above observations indicate that FcεRI signaling is controled by constitutive and by FcγRIIB-dependent negative regulation and that both depend on SHIP1.
Constitutive negative regulation of FcεRI signaling was shown to depend on F-actin skeleton but the molecular basis of the recruitment of SHIP1 by FcεRI is unknown. Conversely, the molecular basis of the recruitment of SHIP1 by FcγRIIB is well established but the cellular basis of FcγRIIB-dependent negative regulation of FcεRI signaling is unknown. We investigated here the role of the sub-membranous F-actin skeleton in the inhibition of IgEinduced mast cell activation by FcγRIIB. We found that the F-actin skeleton is necessary for
Materials and methods
Cells and transfectants. The rat mast cells RBL-2H3 were cultured in DMEM or RPMI supplemented with 10% FCS, 100 IU/ml penicillin, 100 µg/ml streptomycin and 2 mM Lglutamine. Culture reagents were from Gibco-BRL (Paisley, Scotland, UK Supernatants (cytosolic fraction) were collected, and pellets were resuspended and incubated for 15 min in Triton X-100 (TX-100) lysis buffer (10 mM Tris pH 7.4, 50 mM NaCl, 1% TX-100, 1 mM Na 3 VO 4 , 5 mM NaF, 5 mM sodium pyrophosphate, 0.4 mM EDTA, 10 µg/ml aprotinin, 10 µg/ml leupeptin and 1 mM PMSF). Cell lysates were centrifuged at 15,000 g for β-hexosaminidase release. Cells were sensitized with 0.1 µg/ml IgE anti-DNP with or without 2 µg/ml 2.4G2 F(ab') 2 for 18 h at 37°C. When indicated, 0.25 µg/ml latrunculine B was added in cultures. Cells were washed, pre-warmed for 15 min at 37°C with or without 0.25 µg/ml latrunculin B, and stimulated with 10 µg/ml TNP 13 -MAR F(ab') 2 for 30 min at 37°C. Reactions were stopped on ice and supernatants were collected. β-hexosaminidase
release was measured by incubating supernatants with p-nitrophenyl-N-acetyl-D-
glucosaminide (a β-hexosaminidase substrate) (Sigma) for 2 h at 37°C. Reactions were stopped with glycine 0.2 M pH 10.7, and absorbance was measured at 405 nm. The percentages of β-hexosaminidase released in supernatants were calculated using as 100 % β-hexosaminidase contained in aliquots of cells lysed in 1 % TX-100.
Results

F-actin skeleton disruption decreases FcγRIIB-dependent inhibition of IgE-induced mediator release by mast cells.
To investigate the role of the F-actin skeleton in FcγRIIB-dependent negative regulation of IgE-induced mast cell activation, we examined FcγRIIB-dependent inhibition in cells treated with a drug that prevents F-actin polymerization. Cells were incubated with latrunculin B under conditions that had no effect on mediator release observed following FcεRI aggregation. This treatment reduced the amount of F-actin but not the expression of FcγRIIB and FcεRI (Fig. 1A ). FcγRIIB-dependent inhibition of β-hexosaminidase release observed in untreated cells was decreased in latrunculin-treated cells (Fig. 1B ). An intact Factin skeleton is therefore required for optimal inhibition of mast cell activation by FcγRIIB.
When coaggregated or aggregated, FcγRIIB and FcεRI translocate into the F-actin skeleton compartment.
To investigate whether FcγRIIB can interact with the F-actin skeleton upon coaggregation with FcεRI, cytosol, membrane and F-actin skeleton fractions were prepared and analyzed by Western blotting. In unstimulated cells, the F-actin-associated protein α-actinin was recovered in the F-actin skeleton fraction, but also in the cytosol fraction. Cyclin D3 was found in the cytosol fraction only. FcγRIIB were recovered in the membrane fraction only ( Fig. 2A ).
When quantitated with 125 I-labeled 2.4G2 F(ab') 2 in resting cells, most FcγRIIB were also recovered in the membrane fraction (75%), but some were recovered in the cytosol fraction (15%) and in the F-actin skeleton fraction (10%). Following coaggregation with FcεRI, two-fold less FcγRIIB were recovered in the membrane fraction while five-fold more were recovered in the F-actin skeleton fraction, reaching 50% of total FcγRIIB (Fig. 2B ). The same was observed following FcγRIIB aggregation, indicating that FcγRIIB do not need to be coaggregated with FcεRI to translocate into the F-actin skeleton compartment (Fig. 2C ).
Noticeably, upon aggregation, FcγRIIB with a deletion of their whole intracytoplasmic domain (FcγRIIB-IC -), redistributed in the F-actin skeleton fraction in the same proportion as intact FcγRIIB (Fig. 2C) .
Likewise, when quantitated using 125 I-IgE, the proportion of FcεRI recovered in the F- 
Following coaggregation with FcεRI, FcγRIIB remain excluded from LD-DRM.
Several raft markers like LAT, lyn and GM1, were recovered not only in the membrane fraction, but also in the F-actin skeleton fraction (data not shown). This observation raised the possibility that FcγRIIB interacted with lipid rafts, rather than with the F-actin skeleton. To discriminate between these two possibilities, cells were lysed in TX-100 and cell lysates were fractionated by ultracentrifugation in discontinuous sucrose gradients. Western blot analysis shows that, in unstimulated cells, the raft marker GM1 was recovered in fractions 3-4
containing LD-DRM (the interface between the low-and the middle-density solutions), whereas the F-actin skeleton marker α-actinin was recovered in fractions 10-11 (the high-density solution). FcγRIIB had the same distribution as FcεRI. The vast majority of receptors were recovered in fractions 8-11. Minute amounts of receptors were recovered in fractions 3-4. SHIP1, the effector phosphatase of FcγRIIB-dependent inhibition, was detected in fractions 10-11 (Fig. 3A) . To quantitate FcγRIIB in density fractions following coaggregation with FcεRI, cells were incubated with 125 I-labeled 2.4G2 F(ab') 2 . They were sensitized with mouse IgE anti-DNP, challenged with TNP 18 -MAR F(ab') 2 or not, and lysed in TX-100 (two concentrations were used). Lysates were fractionated as above. In unstimulated cells, FcγRIIB had the same distribution when assessed by radioactivity as when assessed by Western blotting. Following coaggregation with FcεRI, the amount of FcγRIIB recovered in LD-DRM did not increase, but rather decreased. Under these conditions, 75% FcγRIIB were recovered in fraction 11, at the bottom of the gradient (Fig. 3B, right panel) . To check that we were able to detect receptor translocation into LD-DRM, we analyzed the translocation of FcεRI after receptor aggregation. Cells were incubated with 125 I-labeled mouse IgE anti-DNP and stimulated with TNP 18 -MAR F(ab') 2 . As previously described, the amount of FcεRI recovered in LD-DRM fractions increased following receptor aggregation. The absolute amounts of FcεRI recovered in these fractions depended on the concentration of detergent, but not the relative amounts (Fig. 3C ).
Altogether, these results indicate that, when coaggregated with FcεRI, FcγRIIB translocate into material recovered at the bottom of the highest density fraction containing Factin skeleton markers, but not detectably into LD-DRM.
The F-actin skeleton compartment contains the high-molecular weight isoform of SHIP1 that interacts with the actin-binding protein filamin-1 in resting cells.
SHIP2 was reported to associate constitutively with the F-actin skeleton in COS7 cells, and this association was found to be mediated by the actin-binding protein, filamin-1.
We investigated whether these findings could apply to SHIP1 in mast cells. Subcellular fractionation analysis of resting mast cells revealed that, although most SHIP1 was recovered in the cytosol fraction, SHIP1 was also recovered in the F-actin skeleton fraction. SHIP1 was hardly detectable in the membrane fraction. Noticeably, the two main isoforms of SHIP1 were found in comparable amounts in the cytosol fraction whereas the high-molecular weight isoform was predominant in the F-actin skeleton fraction (Fig 4A) . Because SHIP2 was reported to constitutively associate with the F-actin skeleton via the actin-binding protein filamin-1 in COS7 cells (28), we compared the cellular localization of filamin-1 and SHIP1 in resting cells and we investigated whether these two proteins can interact. Filamin-1 was recovered with SHIP1 both in the cytosol and in the F-actin skeleton fraction (Fig. 4A ).
SHIP1 was colocalized with filamin-1, both in the cytosol and in cortical areas, when examined by confocal microscopy (Fig. 4B ). SHIP1 coprecipitated with filamin-1 in resting cells (Fig. 4C) . Noticeably, the high-molecular weight isoform of SHIP1 preferentially coprecipitated with filamin-1, whereas the low-molecular weight isoform was predominant in whole cell lysate (Fig. 4D) . These results altogether indicate that the F-actin skeleton contains the high-molecular weight isoform of SHIP1 that is constitutively associated with the actinbinding protein filamin-1.
FcγRIIB and SHIP1 interact with filamin-1 upon coaggregation with FcεRI.
Interestingly, the high-molecular weight isoform of SHIP1 preferentially coprecipitated also with FcγRIIB following coaggregation with FcεRI (Fig. 4D) . Since
FcγRIIB translocate into the F-actin skeleton compartment and since the high-molecular weight isoform of SHIP1 is constitutively associated with filamin-1, we investigated whether
FcγRIIB associate with filamin-1 upon coaggregation with FcεRI. We failed to detect any coprecipitation between FcγRIIB and filamin-1 (data not shown). We therefore examined In the majority of cells, FcR patches had a small size but large FcR patches were also seen. Noticeably, the percentage of cells with patches larger than 2 µm increased with time ( Fig. 6A) , suggesting that FcR patches progressively enlarge during the minutes following FcεRI/FcγRIIB coaggregation. SHIP1 remained clustered with FcγRIIB and FcεRI in large patches whereas, surprisingly, both filamin-1 and F-actin were excluded (Fig 6B) . When examined in individual cells, filamin-1 was not colocalized with large SHIP1 aggregates (Fig.   6C ). Quantitative analysis of filamin-1 and SHIP1 redistribution as a function of the size of FcR patches revealed that FcR patches containing filamin-1 had an average size of 1.4 ± 0.9 µm, whereas FcR patches not containing filamin-1 had an average size of 3.7 ± 0.9 µm.
SHIP1 was observed in FcR patches whatever their size (0.8 to 5 µm) (Fig. 6D) .
Altogether, these results show that, upon coaggregation of FcγRIIB with FcεRI, small clusters containing FcγRIIB, FcεRI, SHIP1, filamin-1 and F-actin form first, from which filamin-1 and F-actin are excluded as clusters enlarge with time at the cell surface.
Discussion
We show here that the F-actin skeleton is necessary for FcγRIIB-dependent negative regulation of IgE-induced mast cell activation and contains the effector molecule of inhibition, SHIP1, which is constitutively associated with the actin-binding protein filamin-1.
The We found that SHIP1, which is required for both regulatory processes, is associated with the F-actin skeleton in resting cells. SHIP1 was indeed present in the cytosol, as expected, but also in the F-actin skeleton as revealed by biochemical analysis of subcellular fractions. SHIP1 was also colocalized with the actin-binding protein filamin-1, both in the cytosol and, together with F-actin, in cortical areas as shown by confocal microscopy. Finally, SHIP1 coprecipitated with filamin-1 in whole cell lysates (Fig. 3B ) and in cytosolic subcellular fractions (data not shown). These data suggest that a fraction of SHIP1 is associated with the sub-membranous F-actin via filamin-1. We however failed to coprecipitate SHIP1 with filamin-1 in the F-actin skeleton fraction. Very low amounts of soluble proteins were, indeed, recovered in this fraction, and the amount of immunoprecipitated filamin-1 may be too low for the coprecipitation of SHIP1 to be detectable. We noticed however that, although comparable amounts of the high-and low- When FcεRI and FcγRIIB were coaggregated, filamin-1 redistributed with FcRs and with SHIP1 in small membrane patches. These results support the hypothesis that, once associated with F-actin, FcγRIIB recruit filamin-bound SHIP1. Noticeably, we did not detect any substantial translocation of SHIP1 from the cytosol to membrane areas by confocal microscopy analysis (Fig. 5A) . Likewise, fractionation analysis did not reveal any translocation of SHIP1 from the cytosol to membrane or F-actin skeleton (data not shown).
As SHIP1 was hardly detected in the membrane fraction, these observations indicate that 7 mm
